On May 23, 2024, Radar Therapeutics, a biotech company developing smart programmable medicines, announced the completion of an oversubscribed $13.4 million in seed financing led by NfX Bio. Major investors Eli Lilly and Company, Biovision Ventures, and KdT Ventures also joined the round, with participation from PearVC, BEVC, and other investors. Wilson Sonsini Goodrich & Rosati advised Radar Therapeutics on IP matters related to the transaction.

Radar Therapeutics is developing advanced genetic and mRNA-based treatments that employ RNA sensors. These sensors regulate their expression based on other RNAs present in the cell, allowing precise and timely delivery of drug payloads to the intended cells. This controlled process minimizes systemic toxic side effects by preventing the therapy from affecting non-target cells. Through their RADAR platform, Radar Therapeutics aims to create 'smart', scientifically engineered precision treatments. The financing will support advancement of Radar Therapeutics’ internal programs, team expansion, and partnering.

The Wilson Sonsini team that advised Radar Therapeutics on IP matters related to the transaction includes:

Patents and Innovations
Ali Alemozafar
Vern Norviel
Rona Lamiquiz
Brandon Tavshanjian

Technology Transactions
Kathy Ku
Sarah (Siedlak) Walker

For more information, please see Radar Therapeutics' news release. Additional coverage can be found on BioSpace and Genetic Engineering & Biotechnology News.